<p>SD = single dose; RD = repeat dose.</p><p><sup>2</sup>Amyloid-related imaging abnormality-hemorrhage (ARIA-H)</p><p><sup>1</sup>Amyloid-related imaging abnormality-edema (ARIA-E);</p><p>Summary of most frequently reported adverse events.</p
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been ai...
Introduction: Alzheimer's disease is a neurodegenerative disease that initially manifests itself pri...
<p>SAE = serious adverse event; TEAE = treatment-emergent adverse event.</p><p>1 Subjects who ex...
Amyloid-related imaging abnormalities (ARIA) are adverse events reported in Alzheimer’s disease tria...
BACKGROUND AND PURPOSE: AD is one of the few leading causes of death without a disease-modifying dru...
<p>The AE experienced during the study are listed.</p><p><sup>*</sup>Frequency: 1 = Intermittent, 2...
Background: Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheim...
IntroductionAmyloid-related imaging abnormalities (ARIA) are a common, dose-dependent effect of amyl...
<p>Most frequently reported treatment emergent adverse events and serious adverse events, as reporte...
amyloid-related imaging abnormalities in a cognitively normal adult An 81-year-old cognitively norma...
Importance: The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust ...
Introduction: Amyloid-related imaging abnormalities–edema (ARIA-E) is associated with anti-amyloid b...
<p><sup>1</sup> Data presented are number (%) of patients.</p><p><sup>2</sup> MedDRA 12.0.</p><p>Sum...
To investigate the natural history and outcomes following treatment for spontaneous amyloid-related ...
<p>Abbreviations: AE = adverse event, FBS = fetal bovine serum, GVHD = graft versus host disease, MR...
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been ai...
Introduction: Alzheimer's disease is a neurodegenerative disease that initially manifests itself pri...
<p>SAE = serious adverse event; TEAE = treatment-emergent adverse event.</p><p>1 Subjects who ex...
Amyloid-related imaging abnormalities (ARIA) are adverse events reported in Alzheimer’s disease tria...
BACKGROUND AND PURPOSE: AD is one of the few leading causes of death without a disease-modifying dru...
<p>The AE experienced during the study are listed.</p><p><sup>*</sup>Frequency: 1 = Intermittent, 2...
Background: Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheim...
IntroductionAmyloid-related imaging abnormalities (ARIA) are a common, dose-dependent effect of amyl...
<p>Most frequently reported treatment emergent adverse events and serious adverse events, as reporte...
amyloid-related imaging abnormalities in a cognitively normal adult An 81-year-old cognitively norma...
Importance: The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust ...
Introduction: Amyloid-related imaging abnormalities–edema (ARIA-E) is associated with anti-amyloid b...
<p><sup>1</sup> Data presented are number (%) of patients.</p><p><sup>2</sup> MedDRA 12.0.</p><p>Sum...
To investigate the natural history and outcomes following treatment for spontaneous amyloid-related ...
<p>Abbreviations: AE = adverse event, FBS = fetal bovine serum, GVHD = graft versus host disease, MR...
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been ai...
Introduction: Alzheimer's disease is a neurodegenerative disease that initially manifests itself pri...
<p>SAE = serious adverse event; TEAE = treatment-emergent adverse event.</p><p>1 Subjects who ex...